Marinova's algal extract shows proven relief for BPH symptoms, opening a new nutraceutical avenue
Executive summary: Marinova conducted a clinical study demonstrating that its proprietary algal extract alleviates the symptoms of benign prostatic hyperplasia (BPH). The result provides a non‑pharmaceutical, natural‑product option for a common urological condition, potentially creating a new market segment in supplements and functional foods.
Who is involved: Marinova (Australian biotechnology company), trial participants with BPH, and the investigating clinical researchers.
Likely next: Marinova will likely pursue regulatory clearance for health‑claim labeling and seek partnerships with supplement or pharma companies for product development.
An Australian biotech firm, Marinova, reported that a randomized, double‑blind clinical trial found its unique marine algae extract significantly reduces symptoms of benign prostatic hyperplasia. The press release was issued simultaneously in German, Spanish and French, indicating a broad communications push. No safety concerns were highlighted in the announcement.
Timeline
- — Algenextrakt lindert nachweislich Prostatabeschwerden (PR Newswire)
Analysis — what this means
Sectors affected
- Dietary supplements
- Urology pharmaceuticals
- Functional foods
Historical parallels
- Cranberry extract used for urinary tract health claims since the early 2000s
- Saw palmetto extracts have been marketed for BPH relief since the 1990s
Key entities
Sources
- Algenextrakt lindert nachweislich Prostatabeschwerden — PR Newswire